22-Year-Old Male with Pink Plaques on the Face

  • Kevin K. Wu
  • Michael P. Lee
  • Jashin J. Wu
Part of the Clinical Cases in Dermatology book series (CLIDADE)


Facial psoriasis presents with erythematous, indurated, well-demarcated plaques on the face. Due to the visibility of facial psoriasis, it can cause significant psychosocial distress to patients affected. First-line therapies include low-potency topical corticosteroids, vitamin D analogs, topical calcineurin inhibitors, and crisaborole.


Facial psoriasis Vitamin D analog Calcineurin inhibitor Crisaborole Topical corticosteroid 


  1. 1.
    Canpolat F, Cemil BC, Eskioglu F, Akis HK. Is facial involvement a sign of severe psoriasis? Eur J Dermatol. 2008;18(2):169–71. Scholar
  2. 2.
    van de Kerkhof PC, Murphy GM, Austad J, Ljungberg A, Cambazard F, Duvold LB. Psoriasis of the face and flexures. J Dermatolog Treat. 2007;18(6):351–60. Scholar
  3. 3.
    Young Park J, Hyun Rim J, Beom Choe Y, Il Youn J. Facial psoriasis: comparison of patients with and without facial involvement. J Amer Acade Dermatol. 2004;50:582–4.CrossRefGoogle Scholar
  4. 4.
    Woo SM, Choi JW, Yoon HS, Jo SJ, Youn JI. Classification of facial psoriasis based on the distributions of facial lesions. J Am Acad Dermatol. 2008;58(6):959–63. Scholar
  5. 5.
    Kim KH, Ahn JY, Park MY, Youn JI. Relation between the Peripherofacial psoriasis and scalp psoriasis. Ann Dermatol. 2016;28(4):422–6. Scholar
  6. 6.
    Beattie PE, Lewis-Jones MS. A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases. Br J Dermatol. 2006;155(1):145–51. Scholar
  7. 7.
    Ortonne JP, Humbert P, Nicolas JF, Tsankov N, Tonev SD, Janin A, et al. Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 microg g(-1) ointment and calcipotriol 50 microg g(-1) ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas. Br J Dermatol. 2003;148(2):326–33.CrossRefGoogle Scholar
  8. 8.
    Naldi L, Rebora A. Clinical practice. Seborrheic dermatitis. N Engl J Med. 2009;360(4):387–96. Scholar
  9. 9.
    Choonhakarn C, Poonsriaram A, Chaivoramukul J. Lupus erythematosus tumidus. Int J Dermatol. 2004;43(11):815–8. Scholar
  10. 10.
    Lee EB, Lebwohl MG, Wu JJ. Treatment of psoriasis with crisaborole. J Dermatolog Treat. 2018;30:1–2. Scholar
  11. 11.
    Jacobi A, Braeutigam M, Mahler V, Schultz E, Hertl M. Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16-week open-label study. Dermatology. 2008;216(2):133–6. Scholar
  12. 12.
    Lebwohl M, Freeman AK, Chapman MS, Feldman SR, Hartle JE, Henning A, Tacrolimus Ointment Study G. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol. 2004;51(5):723–30. Scholar
  13. 13.
    Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494–503 e496. Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Kevin K. Wu
    • 1
  • Michael P. Lee
    • 2
  • Jashin J. Wu
    • 3
  1. 1.Frank H. Netter MD School of Medicine at Quinnipiac UniversityNorth HavenUSA
  2. 2.Eastern Virginia Medical SchoolNorfolkUSA
  3. 3.Founder and CEODermatology Research and Education FoundationIrvineUSA

Personalised recommendations